Associate ProfessorBarbara de Graaff

Dr Meredith Hodgson Research Fellowship

Menzies Institute for Medical Research

  • Dr Meredith Hodgson Research Fellowship
    Menzies Institute for Medical Research
  • 61 3 6226 4262 (Work)
  • Menzies Institute for Medical Research, Menzies Institute for Medical Research, Medical Science Precinct, Hobart CBD Campuses, TAS

FUNDED PROJECTS

  • GRANT
    The Neurotoxicity Landscape: Mapping Environmental Risk Factors for Parkinson's and MND Prevalence in Australia
    1 Jul 2026 - 30 Jul 2027
    People funded by this grant:
    • de Graaff B,
    • Alty J,
    • Callisaya M,
    • Blizzard C,
    • Breslin M
    Project Total: $110,017; Approximately 90% of Parkinsons and Motor Neurone Disease (MND) cases are due to a combination of environmental and genetic factors. Environmental risk factors that have been linked to increased risk include agricultural pesticides, heavy metals (e.g. manganese) and air traffic-related pollution. Many of these toxins have been shown to induce neurodegeneration through multiple mechanisms. In response, numerous countries have banned these chemicals, however Australia has been slow to follow. For example, paraquat has been banned in 78 countries, yet the Australian regulator has been reviewing a proposed ban for more than 27 years. The aims of this project will be to generate epidemiological data to identify associations between exposure to a broad range of environmental risk factors and Parkinsons and MND. Firstly, we will geographically map Parkinsons and MND cases across Australia. We will then map environmental risk factor variables including land use (e.g. types of agriculture, mining) and air pollution, along with sociodemographic variables (alcohol and tobacco use, chronic health conditions, psychological distress, overweight and obesity). Regression models will assess associations between risk factors and prevalence of Parkinsons and MND. Importantly, we will build an online interactive map to allow users to visualise clusters of Parkinsons, MND, or both, to identify if these are associated with each of the exposures. We will use the National Health Data Hub, a longitudinal dataset that contains health data for almost all Australians (excl WA and the NT). This will be the first research of its kind globally, to bring together multiple neurodegenerative conditions and to identify associations between prevalence of these and a broad range of environmental risk factors. The findings will be critical for informing public health policy, particularly concerning the regulation of persistent environmental toxins. Funded by: Perpetual Trustees - IMPACT Philanthropy Application Program ($110,017); University of Tasmania.
  • GRANT
    Motor Nerone Disease in Australia: generating epidemiological and health economic evidence
    1 Jan 2026 - 31 Dec 2026
    People funded by this grant:
    • Nguyen LTA,
    • de Graaff B,
    • Blizzard C
    Project Total: $20,000; This project aims to generate the first comprehensive national estimates of motor neurone disease (MND) incidence, prevalence, survival, and economic burden in Australia using linked administrative health datasets from the National Health Data Hub, including: hospital admissions, emergency department presentations, MBS, PBS, Aged Care, National Disability Insurance Scheme, and Death Funded by: Donation via Menzies Institute for Medical Research - Donation ($20,000); University of Tasmania.
  • GRANT
    Implementing ParkinsonNet to improve equitable access to high quality care for people with Parkinson's Disease in rural and remote Australia
    1 Sep 2025 - 31 Aug 2030
    People funded by this grant:
    • Callisaya M,
    • McGinley J,
    • Klaic M,
    • Russell T,
    • Bloem B
    Project Total: $2,883,922; Parkinsons Disease (PD) is a progressive neurological condition with no cure. PD causes major disability and significantly increase the risk of falls, hospitalisation and need for care. There is strong evidence that therapies delivered by expert allied health professionals according to guidelines can reduce adverse outcomes, extend active life years and delay transition to residential care. The challenge is that in Australia there are no guidelines for PD care, and people with PD report difficulty finding and accessing expert care, especially those living in rural and remote areas. ParkinsonNet is an innovative evidence-based and cost-effective model originating from the Netherlands that improves access to high-quality networked care and improved health outcomes (e.g., reduced disability, rates of hospitalisation, lower healthcare costs). It supports health professionals deliver, quality care through training, mentoring, visible networks, audits and continuous improvement. It has been successfully implemented in the USA and Europe, and is recognised internationally as a gold standard model. However, challenges to implementation in the Australian rural and remote context exist, and include travel distance and a lack of a specialist health workforce. The aims of our study are to: 1) identify the barriers, facilitators and required adaptions to ParkinsonNet for successful implementation in rural/remote Australia; 2) evaluate reach, adoption, acceptability, sustainability and potential for scale-up and 3) determine changes to: a) health professional knowledge, self-efficacy and evidence-based practice; and b) health outcomes and experiences for people with PD. The outcomes of the project will be improved access to high-quality care through the ParkinsonNet model which has proven health outcomes; improved workforce capability and capacity, and reduced healthcare costs. The output will be a national centre and implementation roadmap ready for scale-up across the country. Funded by: Medical Research Future Fund - Grant - Dementia, Ageing and Aged Care Mission ($2,873,778); University of Tasmania.
  • GRANT
    Bloodborne virus and sexually transmissible infections testing in Tasmania: a data linkage study
    Royal Hobart Hospital Research Foundation1 Jan 2025 - 30 Sep 2026
    People funded by this grant:
    • Stephens N,
    • Bennett-Daly G,
    • Cooley L,
    • Owen L,
    • de Graaff B
    Project Total: $24,000; Improving sexual and reproductive health remains a global health priority and is reflected in the Sustainable Developments Goals agenda for 2030. Australia's Blood Borne Viruses and Sexually Transmissible Infections Research Strategy supports relevant research to reduce the incidence of BBV and STI in Australia. A major concern is that BBVs and STIs remain undiagnosed and untreated. A key strategy is to increase diagnoses of BBVs and STIs through wider testing. To explore the BBV (hepatitis C, hepatitis B, HIV) and STI (chlamydia, gonorrhea, syphilis) testing practices in Tasmania, this study will undertake data linkage of all BBV and STI tests conducted within Tasmanian laboratories from 1 January 2014 to 31 December 2023 to measure population levels of testing, retesting and test positivity, and report on any demographic and health services differences in testing trends. This study will also link BBV and STI testing data in women aged 15 to 44 years with the Tasmanian Perinatal Data Collection to identify any gaps in testing by area of residence, age, and socioeconomic indicators. The findings will enable targeted advice to healthcare providers to increase testing where it is required, as well as targeted messaging to at risk populations. The resultant increase in testing will lead to reduced mortality and morbidity relating to BBVs and STIs in Tasmania, minimise the personal and social impact of BBVs and STIs on the Tasmanian population, and increase the likelihood of meeting the targets to eliminate HIV, hepatitis C, and hepatitis B as a public health threat in Tasmania. This project will also result in equitable antenatal BBV and STI testing of pregnant women in Tasmania and will increase the likelihood of all pregnant women in Tasmania being tested and treated for syphilis, thereby increasing the likelihood of congenital syphilis being eliminated in the Tasmanian population. Funded by: Royal Hobart Hospital Research Foundation - Grant-Project ($24,000); University of Tasmania.
  • GRANT
    Prevalence and costs of Parkinsons Disease in Tasmania and Australia
    1 Jan 2025 - 30 Jun 2027
    People funded by this grant:
    • de Graaff B,
    • Alty J,
    • Callisaya M,
    • Heath R,
    • Zhao T
    Project Total: $24,998; Parkinsons Disease (PD) is a progressive, chronic neurological condition of ageing, causing major disability, with no cure or treatment to slow disease progression. It is the fastest growing neurological condition globally, increasing by 155% over the last three decades. PD is characterised by motor (tremors, muscle stiffness, impaired mobility and speech) and non-motor (cognitive impairment, disrupted sleep, pain, and autonomic dysfunction) symptoms. For Australia, prevalence of PD is not well understood. Few studies have been undertaken, with national estimates ranging between 41,000 to 200,000. In turn, the economic impact of PD is also not well understood. Two Australian studies have been published, one based on a small sample of people with PD (pwPD) (n=87) in 2012, and a second using 2000/01 data, which estimated an annual cost of $568million. In this context, the aims of this project are: 1. What is the prevalence of PD in Tasmania and Australia? 2. What are the annual costs of PD to the health systems in Tasmania and in Australia? Funded by: Royal Hobart Hospital Research Foundation - Grant-Project ($24,998); University of Tasmania.
  • GRANT
    The impact of geographical and socioeconomic disparity on colorectal cancer outcomes in Tasmania
    1 Jan 2025 - 31 Dec 2026
    People funded by this grant:
    • Allen B,
    • Ahuja K,
    • de Graaff B,
    • Obamiro K
    Project Total: $13,250; Colorectal cancer (CRC) is the second most prevalent cancer diagnosed in Australia and the number of new cases is increasing every year (AIHW, 2023). Timely diagnosis of CRC leads to better outcomes for patients however, Tasmania boasts the longest diagnostic intervals of approximately 240 days on average, doubling national targets. By examining factors influencing timely diagnosis and survival outcomes, this research will guide clinical and public health policy with the aim to reduce the burden of CRC on the Tasmanian population. This study will utilise data routinely collected in Tasmania. Data linkage of population-based de-identified information will be utilised, avoiding any involvement or contacts with individuals. Funded by: Clifford Craig Foundation - Grant-Research ($13,250); University of Tasmania.
  • GRANT
    Counting what counts: using a national cohort study to develop, validate and apply an Indigenous Quality of Wellbeing Utility Index and quantifying key determinants of health
    1 Jul 2024 - 30 Jun 2029
    People funded by this grant:
    • Lovett R,
    • de Graaff B,
    • Campbell J,
    • Thurber K,
    • Brown A
    Project Total: $1,789,516; This collaborative project aims to develop and validate an Indigenous-specific health state utility instrument. Currently, no utility instruments exist that can be applied in health economic evaluations that relate to Aboriginal and Torres Strait Islander peoples wellbeing. Current instruments have been developed based on Western concepts of wellbeing, and do not capture important aspects such as culture, spirituality, and Country. This study will develop the Indigenous Quality of Wellbeing utility instrument, validate this and apply it in a nested longitudinal study to generate health state utility values for a large cohort of Aboriginal and Torres Strait Islander people. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Clinical Trial and Cohort Studies; Australian National University; University of Tasmania.
  • GRANT
    Targeted care for chronic plantar heel pain: shockwave therapy for bone marrow lesions (the BALSA trial)
    1 May 2024 - 9 Feb 2026
    People funded by this grant:
    • Rogers J,
    • Winzenberg T,
    • Jones G,
    • Halliday A,
    • Aitken D
    Project Total: $27,000; Our previous research has found that up to 50% of people with chronic plantar heel pain (CPHP) have a bone marrow lesion (BML) in the heel bone- a high signal lesion visible on MRI. These lesions were associated with having heel pain in a dose-response manner and when they shrink over time, with better pain and function outcomes one year later. This trial proposes to target these lesions with a type of therapy known as shockwave (radial extracorporeal shockwave therapy). This therapy has been shown to shrink BMLs in other areas, however it has never been tested specifically in a subgroup of BML-positive CPHP participants. We will randomly allocate 90 people with CPHP who also have a BML to receive 3 sessions of either active or sham shockwave. Our primary outcome of interest will be foot pain at 4 months, with secondary outcomes of function, quality of life and BML size at 4 months. This research is important as it will help inform the value of targeted care in a previously unrecognised CPHP subgroup, contributing to our understanding of the role of bone in CPHP. Funded by: Donation via Menzies Institute for Medical Research - Donation ($27,000); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    A DATA LINKAGE STUDY OF PRE-HOSPITAL INTENSIVE CARE PARAMEDIC (ICP) CRITICAL RESPONSE UNIT (CRU) IN HIGH PRIORTY ATTENDANCES (PRECRU)
    1 Feb 2024 - 31 Dec 2027
    People funded by this grant:
    • Fouche F,
    • Makrides T,
    • Flanagan B,
    • Emery J,
    • McDermott M
    Project Total: $0; The proposed study, titled 'A Data Linkage Study of Pre-Hospital Intensive Care Paramedic (ICP) Critical Response Unit (CRU) in High Priority Attendances (PRECRU),' aims to evaluate the impact of implementing Intensive Care Paramedic Critical Response Units (ICP CRUs) within the prehospital care system in Tasmania. This observational study will utilize a nested case-control design to compare patient outcomes between those attended by ICP CRU responders and those attended by traditional ambulance services. The primary objective is to assess whether the deployment of ICP CRUs reduces in-hospital mortality rates among critically ill patients in the Hobart region of Tasmania. Secondary objectives include comparing the types and frequencies of critical interventions, time to initiation of care, length of hospital stay, and the health economic impact of the ICP CRU model. This study is expected to provide evidence on the effectiveness of specialized paramedic teams with enhanced clinical skills and leadership capabilities in improving patient outcomes in prehospital settings. Funded by: Tasmanian Ambulance Service; Qatar University; University of Tasmania.
  • GRANT
    Improving outcomes for Tasmanians diagnosed with lung cancer
    1 Jan 2024 - 31 Dec 2027
    People funded by this grant:
    • Cox I,
    • Harkness N,
    • Van Dam P,
    • Palmer A,
    • de Graaff B
    Project Total: $449,997; This project driven by clinicians concerns regarding delays experienced by lung cancer patients. Tasmanian lung cancer patients experience some of the worst outcomes nationally. Timely diagnosis and treatment can improve survival and quality of life. To address this, we will investigate patient and service delivery factors that influence outcomes with the aim of co-designing and piloting strategies to improve the outcomes for Tasmanians diagnosed with lung cancer Funded by: Royal Hobart Hospital Research Foundation - Grant-Major Project ($449,997); University of Tasmania.
  • GRANT
    Identifying Advanced Liver Fibrosis in Primary Care
    1 Feb 2023 - 31 Jan 2027
    People funded by this grant:
    • Adams L,
    • de Graaff B,
    • Nguyen LTA
    Project Total: $2,550,696; Chronic liver disease effects 1 in 4 Australians and may lead to advanced liver fibrosis which is typically asymptomatic and not detected by routine tests. Under-recognition of advanced liver fibrosis precludes the opportunity for risk-stratification, treatment, preventative and surveillance strategies to reduce morbidity. Despite the availability of accurate liver fibrosis tests, there is a lack of implementation in primary care where the bulk of liver disease exists. To overcome this, we will assess the real-world effectiveness, cost and implementation context of an integrated liver fibrosis detection pathway in at-risk patients in primary care. This will be examined via a multi-centre cluster RCT of 42 urban and rural general practices randomly assigned to usual care or a liver fibrosis detection pathway. This will consist of a patient identification and diagnostic pathway, integrated into GP practice management software and aided by a decision support system. The efficacy endpoint will be the proportion of patients with risk factors for chronic liver disease with newly diagnosed advanced liver fibrosis at 12 months. We will also determine the cost-effectiveness of our approach in reducing liver-related mortality, and the implementation context by performing a process evaluation using the RE-AIM framework in order to guide rapid translation into clinical care. We will provide evidence for clinical pathway development and real-world cost-effectiveness data which is critical for adoption and funding. The intervention consists of current technology incorporated into existing software platforms, supporting a rapid implementation. Moreover, the process evaluation will provide the platform to maximise successful implementation strategies in the future. Our collaborative multi-disciplinary team is well-placed to translate our findings and influence government policy to enable wide-spread implementation. Funded by: Medical Research Future Fund - Grant-Clinical Trial Activity Initiative; University of Western Australia; University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    The Healthy Newborn Project: Towards improved prenatal care in rural Australia through access to antenatal point-of-care ultrasound (APoCUS) and empowerment of healthcare workers
    1 Jan 2023 - 31 Jan 2025
    People funded by this grant:
    • de Graaff B,
    • Cox I,
    • Dinh TTN
    Project Total: $40,600; There is inequitable access to ultrasound services in rural communities. The Healthy Newborn Project will train Aboriginal healthcare workers to use bedside ultrasound on pregnant women. These scans can track the healthy growth of unborn babies, assist in planning care, and identify life-threatening pregnancy complications to guide timely referral to specialist care. Funded by: University of South Australia ($40,600); University of Tasmania.
  • GRANT
    The right to rehabilitation for people with dementia: tackling stigma and implementing evidence-based interventions
    1 Jul 2022 - 31 Jan 2026
    People funded by this grant:
    • Callisaya M,
    • de Graaff B
    Project Total: $1,015,820; Dementia is one of the major causes of disability in older people. The World Health Organization recognises that rehabilitation may be needed by anyone with a disability (not just after an acute event) including people with dementia. Our team has led the field internationally showing that rehabilitation and reablement can maintain independence and quality of life, but also importantly, reduce care partner stress. However, evidence-based interventions are often denied. This project will move from generating evidence to implementation, ensuring that people with dementia have equal access to quality health care in order to live at home for as long as possible. The overall aim of our study is to co-design and evaluate a program of solutions (INCLUDE) to improve access to rehabilitation and reablement treatments for vulnerable people living with dementia in the community. We will do so by: 1) reducing stigma and ensuring health workers have the knowledge to provide clients with early referral and care tailored to their needs, 2) empowering people with dementia and their care partner to ask for such interventions and 3) promote systematic collaboration between primary care, providers and dementia services, as well as a community of practice to facilitate referral pathways and learnings. The output of this project will be a package of freely available solutions to improve access to evidence-based rehabilitation treatments for people with dementia to improve their function and quality of life. Funded by: Medical Research Future Fund - Grant - Dementia, Ageing and Aged Care Mission ($614,980); University of Tasmania.
  • GRANT
    Eliminating hepatitis B in remote Indigenous settings: generating health economic evidence
    1 Jan 2022 - 31 Dec 2026
    People funded by this grant:
    • de Graaff B,
    • Cowie B,
    • Campbell J,
    • Wills K,
    • Stephens N
    Project Total: $750,738; Chronic hepatitis B (CHB) is endemic across Indigenous communities in the Northern Territory (NT), with prevalence between 2-5%. Of this group, up to 25% will die from decompensated cirrhosis or liver cancer without care and treatment. In turn, liver disease is the third leading factor contributing to the gap in life expectancy between Indigenous and non-Indigenous Australians. In 2017 the NHMRC funded the Hep B PAST Partnership Project (GNT1151837), which aims to eliminate CHB from NT Indigenous Australians. This is being achieved through two mechanisms: improvement of CHB health literacy amongst participating Indigenous communities and healthcare providers; and transition of CHB care to a primary healthcare based, co-ordinated chronic disease model supported by the establishment of a CHB clinical register. The preliminary results of the Hep B PAST Project have demonstrated a highly effective model of care to increase rates of CHB diagnosis, treatment and community education. The Hep B PAST Project will be completed in mid-2023. To successfully eliminate hepatitis B, it is now critically important to transition this care model Territory-wide. Health economic evidence is now required by government to support this. We have developed five studies to generate this evidence: 1: Quantify costs of the Hep B PAST model of care and the status quo approach to CHB care; 2: Quantify quality of life/health state utility values for hepatitis B health states; 3. Develop and validate a health economic disease simulation model for hepatitis B for Indigenous communities; 4: Project clinical outcomes of the Hep B PAST model of care and the status quo up to 2035; 5: Assess the cost-effectiveness of introducing the Hep B PAST model of care as standard practice across the NT. We will develop the first Indigenous-specific health economic model that will be made available to support rapid, robust evaluations to introduce Hep B PAST into other states/territories. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Ideas ($1,501,476); University of Tasmania.
  • GRANT
    Hospital Acquired Complications: prevalence and economic implications
    1 Jan 2022 - 31 Dec 2023
    People funded by this grant:
    • de Graaff B,
    • Hensher M,
    • Campbell J,
    • Otahal P
    Project Total: $61,214; The first principle of health care is to do no harm. Yet approximately 1 in 10 patients continue to experience harmful safety lapses during their care (Slawomirski & Klazinga 2022). In the hospital setting, these adverse events -- also called hospital-acquired complications (HACs) -- include nosocomial infections, inpatient falls, venous thromboembolism and pressure injuries. Not every HAC is preventable, but their incidence can be reduced through clinical risk management strategies, protocols and interventions. These can be highly cost-effective, especially if implemented within a complementary policy and funding framework (Slawomirski & Klazinga 2022). The Australian Commission on Safety and Quality in Health Care has listed 16 priority HACs that are common and amenable to reduction. The use of the condition onset flag (COF) in Australian admitted patient data makes it possible to determine if a diagnosis was pre-existing or of it was acquired during the episode of care. While some HACs result in premature death, most increase patient morbidity prolonging length of stay and requiring additional medical and surgical interventions. The cost of this additional care in Australia and other developed countries is estimated at 10% to 15% of hospital expenditure (Ehsani et al 2006; Slawomirski et al 2017). In 2018, the Independent Hospital Pricing Authority (IHPA) introduced a national pricing adjustment scheme where the incremental cost of the ACSQHCs sixteen priority HACs is not funded. However, the additional health needs of harmed patients rarely end at hospital discharge. Many HACs will necessitate more follow-up treatment in outpatient, primary and community care, emergency presentations and even hospital readmissions. Relatively little empirical work has been conducted on these downstream effects and their resulting costs of hospital harm. Also, while frailty, co-morbidities, polypharmacy and length of stay are known to increase likelihood of harm, there may be other patient-related or contextual factors that can be used to manage risk. In addition, the association between patient harm and the emerging field of low-value care has not been studied extensively. Funded by: Donation via Menzies Institute for Medical Research - Donation ($61,214); University of Tasmania.
  • GRANT
    Lung cancer screening in Tasmania
    1 Jan 2022 - 31 Oct 2023
    People funded by this grant:
    • Palmer A,
    • Harkness N,
    • de Graaff B,
    • Walters H,
    • Cox I
    Project Total: $24,945; Tasmania has the second highest rate of lung cancer incidence and mortality in Australia. This project will evaluate risk models for identification of high-risk candidates for lung cancer screening and assess whether a screening programme can be effectively and economically implemented. This will lead to earlier identification and treatment, with higher survival rates for Tasmanians, with potential for cost savings. Funded by: Royal Hobart Hospital Research Foundation - Grant-Project ($24,945); University of Tasmania.
  • GRANT
    Providing high-value care for osteoarthritis patients at the Royal Hobart Hospital (RHH)
    1 Jan 2022 - 31 Dec 2023
    People funded by this grant:
    • Aitken D,
    • Lawler K,
    • Harvie P,
    • O'Brien L,
    • Barton C
    Project Total: $24,943; GLA:D is an international evidence-based education and exercise program for people with knee and hip osteoarthritis. This project will evaluate the implementation of GLA:D through the RHH physiotherapy community outpatient clinics for patients on a joint replacement surgery pathway. It will benefit patients and potentially reduce pressure on elective surgery waiting lists. Funded by: Royal Hobart Hospital Research Foundation - Grant-Project ($24,943); University of Tasmania.
  • GRANT
    The health economic impacts of residential fires on the Tasmanian public healthcare system 2010 to 2020 using a mixed-methods approach
    1 Jan 2022 - 30 Sep 2025
    People funded by this grant:
    • Dinh TTN,
    • Campbell J,
    • Palmer A,
    • Schrale R,
    • Ratcliffe K
    Project Total: $9,945; This is the first collaboration between the Tasmanian Fire Service and the Menzies Institute for Medical Research. Using linked data, this project will investigate epidemiological profiles and health services utilisation regarding residential house fires in Tasmania from 2010 to 2020. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($9,945); University of Tasmania.
  • GRANT
    Viral hepatitis-related morbidity and mortality in Tasmania
    1 Jan 2022 - 31 Mar 2024
    People funded by this grant:
    • de Graaff B,
    • Nguyen LTA,
    • Stephens N
    Project Total: $11,025; The burden of chronic hepatitis B (CHB) and chronic hepatitis C (CHC) in Australia is increasing, with an estimated 450,000 people living with chronic viral hepatitis, representing 2% of the population (1, 2). Viral hepatitis is the leading cause of primary liver cancer, which is now the fastest increasing cause of cancer death of Australians (3-6). Tasmania has fallen behind all other states and territories in meeting targets set out in national strategies. The National Hepatitis B Strategy1 targets for 2022 include 80% of people living with CHB will be diagnosed and 50% will be engaged in care. In 2020 (latest data available), 53% of Tasmanians had been diagnosed, and just 17% were receiving care2. For CHC, approximately 1% of the Tasmanian population is estimated to be living with this condition, however only 47% have received curative treatment2. The current National Hepatitis C Strategy3 has set the target of 65% of people having received treatment by 2022. The World Health Organization will be publishing updated CHB and CHC targets in the coming months. Based on these, the Australian Department of Health will set new targets for 2023-2030. In this context, it is timely for increased focus on viral hepatitis in Tasmania. Funded by: Donation via Menzies Institute for Medical Research - Donation ($11,025); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Prevalence, incidence, risk profiles, and health impacts of residential fires in Tasmania 2010-2020
    1 Jan 2021 - 31 May 2023
    People funded by this grant:
    • Campbell J,
    • Palmer A,
    • de Graaff B
    Project Total: $30,000; This is the first collaboration between the Tasmanian Fire Service and the Menzies Institute for Medical Research. Using linked data, this project will investigate epidemiological profiles and health services utilisation regarding residential house fires in Tasmania from 2010 to 2020. Funded by: Tasmania Fire Service ($30,000); University of Tasmania ($1,981).
  • GRANT
    Using data linkage to estimate the burden of diabetes in Tasmania
    1 Jan 2021 - 13 Dec 2021
    People funded by this grant:
    • Palmer A,
    • Jose M,
    • de Graaff B,
    • Campbell J
    Project Total: $24,969; Using pathology, hospital, emergency department, and mortality data linked from four different datasets in Tasmania, this project will quantify the health economic burden associated with diabetes for the Tasmanian Health System, and identifying potential factors that may be targeted for improved patient outcomes and/or cost savings to government. Funded by: Royal Hobart Hospital Research Foundation - Grant-Project ($24,969); University of Tasmania.
  • GRANT
    Screening for liver cancer in primary care: a systematic review of the evidence
    1 Oct 2020 - 31 Dec 2021
    People funded by this grant:
    • de Graaff B,
    • Roydhouse J
    Project Total: $13,145; The project seeks to review the evidence relating to screening for liver cancer in primary care. In particular, we will seek to identify barriers and facilitators to screening for both patients and providers. The goal of this project is to summarise the evidence in the field, which can provide a basis for customised interventions to improve screening uptake. Funded by: Primary Care Collaborative Cancer Clinical Trials Group - Award - Training Award; University of Tasmania.
  • GRANT
    Association between bush fire-smoke/wood-smoke and hospital usage in Tasmania
    1 Jan 2020 - 31 Jul 2021
    People funded by this grant:
    • Johnston F,
    • de Graaff B,
    • Palmer A,
    • Harkness N,
    • Walters H
    Project Total: $10,000; Poor air quality (indoor and outdoor) has been shown to increase morbidity in populations and as a result increase use of health resources. This study will evaluate the association between bush fire-smoke/ wood-smoke and hospital use in Tasmania. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($10,000); University of Tasmania.
  • GRANT
    NAFLD- screen (Non-alcoholic fatty liver disease: prevalence and screening for type 2 diabetes patients)
    1 Jan 2020 - 31 Dec 2022
    People funded by this grant:
    • de Graaff B,
    • Yee K,
    • Campbell J,
    • Palmer A,
    • Lartey S
    Project Total: $24,999; This study will assess the prevalence of non-alcohol fatty liver disease (NAFLD) in patients with type 2 diabetes and normal liver function tests attending the Royal Hobart Hospital Diabetes Outpatient Clinic. It will further assess the most cost-effective strategy for targeted screening for this patient group. Funded by: Royal Hobart Hospital Research Foundation - Grant-Project ($24,999); University of Tasmania.
  • GRANT
    ANCHOR Project: heAlth ecoNomics and epidemiology of myalgiC encephalomyelitis/ chronic fatigue syndrome
    1 Jul 2019 - 31 Dec 2022
    People funded by this grant:
    • de Graaff B,
    • Campbell J,
    • Nicholl H,
    • Hensher M,
    • Wills K
    Project Total: $155,000; Funded by: Medical Research Future Fund - Grant - Targeted Health System and Community ($155,000); University of Tasmania.